Treatment of Inflammatory Bowel Disease with Biologics

109

References

1. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and
   serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
   Am J Gastroenterol. 2013;108:40–7.


2. Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of cer-
   tolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol
   Hepatol. 2013;12(3):423–31.


3. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certoli-
   zumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807–18.


4. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to
   infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol
   Hepatol. 2004;2:542–53.


5. Vermeire S, Noman M, Van Assche G, et  al. Effectiveness of concomitant immunosuppres-
   sive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut.
   2007;56:1226–31.


6. Dulai PS, Siegel CA, Colombel JF, et  al. Systematic review: monotherapy with antitumour
   necrosis factor alpha agents versus combination therapy with an immunosuppressive for
   IBD. Gut. 2014;63:1843–53.


7. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination ther-
   apy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.


8. Panaccione R, Ghosh S, Middleton S, et  al. Infliximab, azathioprine, or infliximab and
   azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial.
   Gastroenterology. 2011;140:A–202.


9. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab
   is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology.
   2013;146(3):681–8.


10. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn’s
    disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054–61.


11. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose
    intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106:674–84.


12. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces anti-
    bodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology.
    2003;124:917–24.


13. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immu-
    nomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized
    trials. Aliment Pharmacol Ther. 2009;30:210–26.


14. Sandborn WJ, Hanauer SB, Rutgeerts P, et  al. Adalimumab for maintenance treatment of
    Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–9.


15. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s
    disease. N Engl J Med. 2007;357:228–38.


16. Sandborn WJ, Feagan BG, Marano C, et  al. Subcutaneous golimumab maintains clinical
    response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96–
    109.e1.


17. Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response
    and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology.
    2014;146:85–95; quiz e14-5.


18. Dulai PS, Siegel CA, Peyrin-Biroulet L.  Anti-tumor necrosis factor-alpha monotherapy
    versus combination therapy with an immunomodulator in IBD.  Gastroenterol Clin N Am.
    2014;43:441–56.


19. Kopylov U, Al-Taweel T, Yaghoobi M, Bitton A, Lakatos PL, Ben-Horin S, Seidman EG, Afif
    W.  Adalimumab monotherapy versus combination therapy with adalimumab and immuno-
    modulators for Crohn’s disease: a meta-analysis. J Crohns Colitis. 2014;8(12):1632–41.

7 Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF)